← back to database
Third Rock Ventures
Company creation and venture investment in biotech and life sciences; scientific discovery, therapeutics, genomic medicines, drug development, diagnostics and clinical execution for unmet medical needs.
Stage focus
Specialization
Generalist / Specialist
Specialist
Latest fund size
$1.1B — Third Rock Ventures VI
Latest fund vintage
2022
Investing team
- Andrea van Elsas, Ph.D.Partner
- Mary Lynne Hedley, Ph.D.Venture Partner
How to reach them
Notable investments
2025-11-04: Azalea Therapeutics launched with $82M combined seed and Series A financing led by Third Rock Ventures. Firm official post confirms participation. Official current approach page says firm has launched over 70 companies and its Discovery effort includes seed-stage validation before launch.
Sources
thirdrockventures.com/approach ↗thirdrockventures.com/privacy-policy ↗thirdrockventures.com/people/mary-lynne-hedley ↗globenewswire.com/news-release/2025/11/04/3180290/0/en/Azalea-Therapeutics-Launches-with-82-Million-Financing-to-Redefine-Precision-Genomic-Medicines-by-Engineering-Cells-Directly-Inside-Each-Patient.html ↗linkedin.com/posts/third-rock-ventures_congratulations-to-the-azalea-therapeutics-activity-7391468463933890562-I2wi ↗thirdrockventures.com/uploads/press-releases/FundVI_PR_061522.pdf ↗thirdrockventures.com/people/rebecca-mancusi ↗thirdrockventures.com ↗